Hikma Pharmaceuticals Profile

USD 0  0.00%

Hikma Pharmaceuticals Summary

Hikma Pharmaceuticals PLC (HKMPY) is traded on OTC Market in USA. It is located in 1 New Burlington Place and employs 8,464 people. The company currently falls under 'Mid-Cap' category with current market capitalization of 4.57 B. Hikma Pharmaceuticals PLC has 240 M outstanding shares. HIKMA PHARM has accumulated about 249 M in cash with 443 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.07.
Check Hikma Pharmaceuticals Probability Of Bankruptcy

Target Price Odds Analysis

Odds Below 35.95HorizonTargetOdds Above 35.95
?%30 days 35.95 ?%
Based on normal probability distribution, the odds of Hikma Pharmaceuticals to move above current price in 30 days from now is about 0.0% (This Hikma Pharmaceuticals PLC probability density function shows the probability of Hikma Pharmaceuticals Stock to fall within a particular range of prices over 30 days) .

Key Fundamentals

Hikma Pharmaceuticals Against Markets

Current Ratings

Hikma Pharmaceuticals 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
Equity ratings for Hikma Pharmaceuticals PLC are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. The company was founded in 1978 and is based in London, the United Kingdom. Hikma Pharmaceuticals operates under Drug Manufacturers - Specialty Generic classification in USA and traded on OTC Market. It employs 8464 people. more
NameHikma Pharmaceuticals PLC
President and CEO, USAMichael RayaView All
Macroaxis Advice
InstrumentUSA Stock View All
Business Address1 New Burlington Place
ExchangeOTC Market
CIK Number01470628.0
Contact Number44 20 7399 2760
CurrencyUSD - US Dollar

Diversify with Hikma Pharmaceuticals PLC

Build Optimal Portfolios
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Hikma Pharmaceuticals PLC to your portfolio


Hikma Pharmaceuticals Corporate Directors
Pamela Kirby Non-Executive Independent Director, Ph.D
John Castellani Non-Executive Independent Director
Ali AlHusry Non-Executive Director, MBA
Please also check Risk vs Return Analysis. Please also try Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.